


Claims**1. Compounds of Formula (I)**

wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

U is hydrogen, halogen, an alkyl, heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

R¹ is a C₁-C₄-alkyl-, a C₂-C₄-alkenyl-, a C₂-C₄-alkinyl- or a C₃-C₄-cycloalkyl-group,

V-W is a group of formula CH₂CH or CH=C,

X is oxygen or a group of the formula NR², wherein R² is hydrogen, an alkyl-, alkenyl-, alkinyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, hetero-



alkylcycloalkyl-, heterocycloalkyl-, aralkyl- or heteroarylalkyl-group and

R^3 and R^4 independently from each other represent hydrogen, C_1-C_4 -alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

2. Compounds according to claim 1, wherein A is a group of the formula $-C(CH_3)=CHR^5$ or $-CH=CHR^5$, wherein R^5 is a heteroaryl- or a heteroarylalkyl group.

3. Compounds according to claim 1, wherein A is a group of formula (II) or (III)




wherein Q is sulphur, oxygen or NR^7 , wherein R^7 is hydrogen, C_1-C_4 alkyl or C_1-C_4 heteroalkyl, z is Nitrogen or CH and R^6 is OR^8 , NHR^8 , C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkinyl or C_1-C_6 heteroalkyl, wherein R^8 is hydrogen, C_1-C_4 alkyl or C_1-C_4 heteroalkyl.

4. Compounds according to any one of the preceding claims, wherein X is oxygen or NH.


5. Compounds according to any one of the preceding claims, wherein R^1 is methyl or ethyl.

6. Compounds according to any one of the preceding claims, wherein R³ and R⁴ are methyl groups.
7. Compounds according to any one of the preceding claims, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.
8. Compounds according to any one of the preceding claims, wherein G-E is selected from the following groups:



9. Compounds according to any one of the preceding claims, wherein V-W is CH₂CH.
10. Pharmaceutical compositions containing a compound, a pharmacologically acceptable salt, a solvate or a hydrate according to any one of the preceding claims or a prodrug of the compound, the salt, the solvate and/or the hydrate and optionally one or more carriers and/or one or more adjuvants and/or one or more diluents.
11. Use of a compound or a pharmaceutical composition according to any one of the preceding claims for the treatment of cancer
12. Use of a compound or a pharmaceutical composition according to any one of the preceding claims for the manufacture of a medicament for the treatment of cancer.

13. Compounds of formula (IVa), (IVb), (Va) and (Vb),



wherein the groups PG independently from each other represent hydrogen or protecting groups.

14. Use of a compound according to claim 13 for the synthesis of a compound of formula (I).